Surgical resection of cardiac myxoma is the most effective treatment for cardioembolic stroke, though optimal timing and approach are still debated.
This review highlights that while surgical resection is the most effective treatment for cardiac myxoma-related ischemic stroke, optimal timing and individualized management protocols require further research.
Absolute Event Rate: 0% vs 0%
Cardiac myxoma (CM) is the most common type of primary cardiac tumor and a major embolic source of cardioembolic stroke. Two potential causative mechanisms are associated with CM-related ischemic stroke (CM-IS): Embolism from detached tumor debris and metastatic infiltration. The risk factors for embolism from CM remain unclear and are widely debated in the literature. CM-IS often initially presents with central nervous system complications. Diagnosis requires a comprehensive assessment of clinical manifestations, imaging findings, and laboratory test results, with histopathological examination required for a definitive diagnosis. Surgical resection of myxoma is the most effective CM-IS treatment, although the optimal timing and approach remain controversial. This review consolidates the current knowledge on CM-IS, identifies critical risk factors for embolic complications, and discusses contemporary treatment strategies, emphasizing the need for individualized management protocols and further research to improve outcomes in affected patients.
Cai et al. (Wed,) reported a other. Surgical resection of cardiac myxoma is the most effective treatment for cardioembolic stroke, though optimal timing and approach are still debated.